UK markets open in 7 hours 48 minutes
NIKKEI 225
38,229.11 -44.99 (-0.12%) HANG SENG
18,963.68 +487.78 (+2.64%) CRUDE OIL
78.04 -0.22 (-0.28%) GOLD FUTURES
2,368.00 -7.00 (-0.29%) DOW
39,512.84 +837.14 (+2.16%) Bitcoin GBP
49,013.58 +365.95 (+0.75%)
Newron Pharmaceuticals S.p.A. (NP5.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
At close: 05:35PM CEST
| Previous close | 10.24 |
| Open | 10.14 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 9.84 - 10.14 |
| 52-week range | 3.82 - 12.00 |
| Volume | |
| Avg. volume | 7,744 |
| Market cap | 186.578M |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
- Business Wire
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy
- Business Wire
Newron Presents 2023 Financial Results and Provides 2024 Outlook
MILAN, March 19, 2024--Newron Pharmaceuticals announces 2023 year-end financial results and provides 2024 business outlook.
© 2024 Yahoo. All rights reserved.